secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2026-10-15T12:00:17+00:00
Accession:  0001213900-26-109587
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Jasper Therapeutics completes IgAN enrollment for vensobafusp alfa Phase 2; adds FSGS cohort
--------------------------------------------------------------------------------

- 18 IgAN patients enrolled in stage 1 across 3 cohorts: subcutaneous Q2W (n=6), Q4W (n=6) and Q8W (n=6) maintenance dosing.
- Initial interim IgAN data from the Phase 2 basket study expected by year-end 2026; stage 1 assesses safety, tolerability and initial efficacy.
- New FSGS cohort added to the basket study, with first patients anticipated to be dosed in the first quarter of 2027.
- Study runs in China with partner Kira; vensobafusp alfa (KP104) is a bifunctional biologic targeting both alternative and terminal complement pathways.
- CMO Greg Keenan said enrollment completed on schedule; company is exploring additional cohorts in other complement-mediated kidney diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026109587/0001213900-26-109587-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390026109587/ea0308657-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-109587

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer